by Measles was once considered a disease that many countries were close to eliminating. In 2026, however, outbreaks are showing that progress can quickly reverse when vaccination coverage falls, routine immunization is disrupted, and immunity gaps accumulate.
The United States recorded 3,134 confirmed measles cases by September 4, 2026, the country’s highest annual total in more than 35 years. CDC data also show that most U.S. cases are associated with outbreaks.
Bangladesh is facing an even more severe situation. Its 2026 outbreak has become one of the largest measles outbreaks globally, with widespread transmission following disruptions to routine immunization and vaccine delivery.
This resurgence is not simply a public-health problem. It is creating new priorities for vaccine manufacturers, governments, procurement agencies, healthcare systems, distributors, investors, NGOs, and organizations working across the global immunization ecosystem.
Why Are Measles Cases Rising in 2026?
The main issue is not that measles has become harder to prevent. The problem is that too many communities have accumulated immunity gaps.
Measles is highly contagious. WHO and Gavi identify approximately 95% coverage with two doses of measles-containing vaccine as the level needed to prevent sustained outbreaks. Yet global coverage remains below this threshold.
WHO and UNICEF’s latest estimates show that global first-dose measles coverage remained at approximately 84% in 2025, while second-dose coverage continued to improve but remained below the level required to consistently prevent outbreaks.
Several factors are contributing to the renewed spread:
- Declining childhood vaccination coverage
- Missed routine immunization during and after the COVID-19 pandemic
- Vaccine hesitancy and misinformation
- Disrupted healthcare infrastructure
- Supply and procurement challenges
- Conflict and population displacement
- Weak disease surveillance in some regions
- International travel and cross-border transmission
- Insufficient catch-up vaccination
The result is a growing population of children and adults who are susceptible to infection.
The 2026 Measles Outbreak Is a Global Warning
The U.S. situation demonstrates how quickly measles can return when coverage falls.
By September 4, 2026, the U.S. had reported 3,134 confirmed cases. Earlier CDC data showed that approximately 94% of confirmed cases were outbreak-associated.
U.S. kindergarten MMR vaccination coverage has also continued to decline. CDC data released in August 2026 put MMR coverage among kindergartners at approximately 92.4% during the 2025–2026 school year, below the 95% level generally required to maintain strong community protection.
This creates an important commercial and policy question:
How should governments, vaccine manufacturers, healthcare systems, and procurement organizations respond when routine vaccination coverage falls below the level needed to stop transmission?
The answer increasingly involves targeted catch-up campaigns, improved vaccine access, stronger surveillance, public communication, and more resilient vaccine supply chains.
Bangladesh Shows What Happens When Immunization Gaps Become Large
Bangladesh has become one of the clearest examples of how quickly immunity gaps can translate into a major outbreak.
WHO reported that between March 15 and April 14, 2026, Bangladesh recorded 19,161 suspected measles cases and 2,973 laboratory-confirmed cases, with children under five accounting for the majority of reported cases.
By September, the outbreak had continued to place significant pressure on healthcare facilities. Reuters reported more than 166,000 suspected cases and 999 suspected or confirmed measles-related deaths since March, making Bangladesh one of the world’s most significant measles outbreak hotspots in 2026.
The lesson for global healthcare stakeholders is clear:
Routine immunization cannot be treated as a one-time program. It requires continuous coverage, procurement, surveillance, community engagement, and supply-chain resilience.
The Global Immunization Gap Remains Significant
The resurgence comes despite decades of progress.
Gavi reports that measles vaccination has helped prevent millions of deaths. In Africa alone, nearly 19.5 million measles deaths were estimated to have been averted between 2000 and 2024, while more than 500 million children were protected through routine immunization.
However, the remaining immunity gap is substantial.
In Gavi-supported lower-income countries, first-dose measles coverage increased from 78% in 2023 to 80% in 2024, while second-dose coverage increased from 66% to 70%. Both remained well below the 95% threshold.
Gavi also reported that 29 of its 57 supported countries experienced large or disruptive measles outbreaks in 2024.
This creates a long-term need for:
- Routine MMR and MR vaccine supply
- Catch-up immunization programs
- Emergency outbreak response
- Cold-chain infrastructure
- Vaccine procurement planning
- Local manufacturing
- Distribution partnerships
- Disease surveillance
- Community engagement
- Data-driven vaccination targeting
Vaccine Manufacturers Are Central to the Response
The resurgence of measles is increasing the strategic importance of established vaccine manufacturers.
Merck
Merck’s M-M-R II is a live measles, mumps, and rubella vaccine indicated for active immunization against the three diseases in individuals aged 12 months and older. Merck also manufactures ProQuad, a combination measles, mumps, rubella, and varicella vaccine.
Merck’s 2026 financial filing provides an important commercial signal. Worldwide sales of M-M-R II declined 24% in the first six months of 2026, primarily because of lower U.S. demand, while ProQuad sales also experienced changes associated with demand and previous manufacturing delays.
The current outbreak environment could therefore create a different demand pattern across geographies as governments increase catch-up vaccination and outbreak-response activity.
GSK
GSK is another major vaccine manufacturer with measles-containing vaccines in its portfolio, including Priorix and Priorix-Tetra in relevant markets. GSK identifies infectious diseases as one of its four major R&D areas and aims to positively impact 2.5 billion people by the end of the decade.
GSK’s vaccine manufacturing footprint also demonstrates why production capacity and geographical supply resilience matter. Its Belgian operations include major vaccine sites in Wavre, Rixensart, and Gembloux, with more than 8,500 employees across those three sites. GSK reported more than 160 vaccines exported from Belgium to over 160 countries in 2025.
Serum Institute of India
India’s Serum Institute of India is another strategically important player in global vaccine supply.
The company produces measles-containing vaccines, including measles vaccine and MMR products such as Tresivac, and has a major global vaccine manufacturing footprint. Its headquarters and manufacturing operations are based in Pune, India.
For governments and procurement organizations, manufacturers such as Merck, GSK, and Serum Institute illustrate an increasingly important consideration:
Access to vaccines depends not only on demand but also on manufacturing capacity, procurement mechanisms, geographic supply networks, regulatory requirements, and delivery infrastructure.
The Business Question Is Shifting From Demand to Access
The 2026 outbreak environment changes the way stakeholders need to assess the opportunity.
A simple question such as “How many vaccines are needed?” is no longer sufficient.
Decision-makers need to understand:
- Where immunity gaps are largest
- Which countries are increasing procurement
- Which populations require catch-up vaccination
- Which manufacturers have relevant products
- Where manufacturing capacity is available
- How procurement is structured
- Which regions have cold-chain limitations
- Where governments are increasing immunization budgets
- Which NGOs and international organizations are supporting campaigns
- Which markets may require local partnerships
- How outbreak intensity could influence future vaccine demand
This is where healthcare intelligence becomes commercially valuable.
Gavi and the Global Immunization Response
Gavi remains one of the most important organizations influencing vaccine access in lower-income countries.
The organization says it has helped immunize more than 1.2 billion children since its creation and prevented more than 20.6 million future deaths.
Its measles strategy focuses on achieving at least 95% coverage with two doses of measles-containing vaccine, alongside preventive campaigns and outbreak-response activities.
Gavi also supported the Big Catch-Up, which delivered more than 100 million vaccine doses to an estimated 18.3 million children across 36 countries by March 2026. Around 15 million children reached through the initiative had never received a measles vaccine.
For vaccine companies and healthcare investors, these programs provide valuable signals about:
funding availability, country priorities, procurement requirements, target populations, and future vaccine demand.
Who Is Most Exposed to the 2026 Measles Resurgence?
The implications extend well beyond vaccine manufacturers.
Vaccine Manufacturers
Manufacturers need to monitor outbreak hotspots, government tenders, procurement cycles, production capacity, competitive positioning, and demand shifts.
Pharmaceutical and Biotechnology Companies
Companies developing vaccines, diagnostics, delivery technologies, or infectious-disease solutions can identify opportunities created by changing public-health priorities.
Governments and Public-Health Agencies
Governments need accurate surveillance, vaccination coverage analysis, procurement planning, supply forecasting, and outbreak-response intelligence.
NGOs and International Organizations
Organizations supporting immunization programs require country-level information on vulnerable populations, vaccine access, logistics, funding, and campaign performance.
Investors
Investors need to understand which vaccine companies have exposure to public-sector procurement, which manufacturers have scalable production, and which regions could experience sustained demand.
Distributors and Healthcare Supply-Chain Companies
Outbreaks increase the importance of cold-chain capacity, inventory planning, regional distribution, and last-mile delivery.
What This Means for Vaccine Manufacturers in 2026
The measles resurgence creates several strategic priorities for manufacturers.
Capacity planning: Companies need to evaluate whether production capacity can respond to sudden government and NGO procurement requirements.
Geographic expansion: High-risk countries can become strategically important for distribution partnerships and local supply agreements.
Government procurement: Public-sector tenders and international procurement programs can represent critical demand channels.
Product positioning: Manufacturers need to understand differences between MMR, MR, MMRV, and other measles-containing vaccine requirements across countries.
Supply-chain resilience: Manufacturing interruptions, raw-material constraints, cold-chain requirements, and logistics bottlenecks can directly affect outbreak response.
Demand forecasting: Companies need to distinguish routine immunization demand from temporary outbreak-driven demand.
What Investors Should Watch
The measles resurgence creates a different investment environment from traditional pharmaceutical markets.
Investors should monitor:
- Vaccine procurement contracts
- Government immunization budgets
- Manufacturing capacity expansions
- WHO and UNICEF procurement programs
- Gavi-supported country programs
- Outbreak frequency and geographic expansion
- Vaccination coverage trends
- Vaccine manufacturer revenue exposure
- Local manufacturing initiatives
- Supply-chain and cold-chain investments
The key investment question is not simply whether measles cases are rising.
It is whether higher outbreak activity will translate into sustained immunization investment and stronger vaccine procurement across multiple regions.
The Role of Data in Managing Measles Outbreaks
The 2026 resurgence also highlights the importance of integrating multiple datasets.
A useful intelligence framework should combine:
Epidemiology
Confirmed cases, suspected cases, hospitalizations, deaths, outbreak duration, and transmission patterns.
Immunization
First-dose and second-dose coverage, zero-dose children, missed vaccinations, and catch-up campaign performance.
Commercial intelligence
Manufacturers, product portfolios, manufacturing capacity, procurement contracts, partnerships, and distribution networks.
Policy intelligence
Government vaccination policies, public-health funding, regulatory changes, and national immunization strategies.
Supply-chain intelligence
Cold-chain infrastructure, production capacity, shortages, logistics, and local manufacturing.
Competitive intelligence
Company positioning, product differentiation, partnerships, tenders, geographic expansion, and investment.
This combination provides a much stronger decision-making framework than looking at case numbers alone.
How Towards Healthcare Research & Consulting Can Help
The measles resurgence creates a fast-changing environment where healthcare organizations need actionable intelligence rather than disconnected statistics.
Towards Healthcare Research & Consulting can support stakeholders across the vaccine ecosystem with:
Vaccine Competitive Intelligence
Track manufacturers, vaccine portfolios, production capabilities, partnerships, procurement contracts, product positioning, and regional presence.
Outbreak and Epidemiology Intelligence
Monitor country-level outbreaks, vaccination coverage, immunity gaps, disease transmission, hospital burden, and emerging hotspots.
Procurement Intelligence
Identify government tenders, international procurement programs, donor-funded vaccination initiatives, and potential purchasing organizations.
Market Entry and Expansion Strategy
Assess countries where vaccination gaps, government priorities, healthcare infrastructure, and procurement opportunities create potential expansion opportunities.
Supply-Chain Intelligence
Analyze manufacturing locations, distribution networks, cold-chain requirements, supply constraints, capacity expansion, and regional vulnerabilities.
Pipeline and Innovation Intelligence
Track vaccine development, next-generation technologies, clinical programs, partnerships, regulatory developments, and emerging infectious-disease platforms.
Investment and Opportunity Assessment
Evaluate companies, regions, partnerships, procurement trends, and healthcare infrastructure investments to identify commercially relevant opportunities.
Government and Policy Intelligence
Track national immunization strategies, public-health policies, regulatory developments, funding priorities, and international health programs that could affect vaccine demand.
The Bigger Lesson From the 2026 Measles Outbreak
The return of measles is not simply a story about one infectious disease.
It is a warning about what happens when immunization coverage, healthcare infrastructure, public trust, surveillance, funding, and supply chains weaken simultaneously.
The global vaccination system has demonstrated that sustained immunization investment can dramatically reduce measles deaths. But the 2026 outbreaks show that these gains are not permanent.
For vaccine manufacturers, governments, investors, NGOs, distributors, and healthcare organizations, the next challenge is not only responding to today’s outbreaks.
It is identifying where the next immunity gaps are developing and acting before they become major outbreaks.
That requires timely epidemiological data, procurement intelligence, company-level competitive analysis, supply-chain visibility, and country-specific opportunity assessment.
Towards Healthcare Research & Consulting helps healthcare organizations convert these developments into actionable intelligence for strategy, investment, market entry, competitive positioning, and growth.
Frequently Asked Questions
Why are measles cases rising in 2026?
Measles cases are rising primarily because vaccination coverage remains below the level needed to prevent sustained transmission in many populations. Missed vaccinations, declining routine immunization, vaccine hesitancy, healthcare disruptions, and population movement are contributing to immunity gaps.
How many measles cases have been reported in the U.S. in 2026?
The CDC reported 3,134 confirmed U.S. measles cases as of September 4, 2026, the country’s highest annual total in more than 35 years.
What vaccination coverage is needed to prevent measles outbreaks?
WHO and Gavi identify approximately 95% coverage with two doses of measles-containing vaccine as the level needed to prevent sustained measles transmission.
Which companies manufacture measles vaccines?
Major companies involved in measles-containing vaccines include Merck, GSK, and Serum Institute of India, with products and supply arrangements varying by country and immunization program.
What does the measles resurgence mean for vaccine companies?
The resurgence can influence government procurement, outbreak-response demand, catch-up campaigns, manufacturing requirements, supply-chain planning, geographic expansion, and long-term immunization strategies.
How can Towards Healthcare support vaccine and healthcare companies?
Towards Healthcare Research & Consulting can provide vaccine competitive intelligence, outbreak intelligence, procurement analysis, company profiling, supply-chain intelligence, market-entry strategy, pipeline tracking, government-policy analysis, and investment opportunity assessment.
Expert View by Payal Rabde – highlighting the trends shaping the future of healthcare.
Explore the latest healthcare insights, all in one dashboard: https://www.towardshealthcare.com/access-dashboard
